Published in Blood Weekly, August 18th, 2005
This study, involving 40 patients, will be conducted at the Johns Hopkins University School of Medicine in Baltimore.
Sangart's approach to the development of oxygen transport agents employs technology that is the result of more than a decade of peer-reviewed research into the mechanism of oxygen transport by cell-free hemoglobin. Preclinical and clinical studies indicate that Hemospan is free of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.